<h4>Background</h4>Repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor, is approved for ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.